- Home
- ANEB vs PULM Comparison
ANEB vs PULM Comparison
Compare ANEB & PULM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ANEB
- PULM
- Stock Information
- Founded
- ANEB 2020
- PULM 2003
- Country
- ANEB United States
- PULM United States
- Employees
- ANEB N/A
- PULM N/A
- Industry
- ANEB Biotechnology: Pharmaceutical Preparations
- PULM Biotechnology: Pharmaceutical Preparations
- Sector
- ANEB Health Care
- PULM Health Care
- Exchange
- ANEB Nasdaq
- PULM Nasdaq
- Market Cap
- ANEB 36.7M
- PULM 30.9M
- IPO Year
- ANEB 2021
- PULM N/A
- Fundamental
- Price
- ANEB $0.98
- PULM $5.50
- Analyst Decision
- ANEB Buy
- PULM
- Analyst Count
- ANEB 1
- PULM 0
- Target Price
- ANEB $8.00
- PULM N/A
- AVG Volume (30 Days)
- ANEB 37.4K
- PULM 21.4K
- Earning Date
- ANEB 05-14-2025
- PULM 05-09-2025
- Dividend Yield
- ANEB N/A
- PULM N/A
- EPS Growth
- ANEB N/A
- PULM N/A
- EPS
- ANEB N/A
- PULM N/A
- Revenue
- ANEB N/A
- PULM $7,806,000.00
- Revenue This Year
- ANEB N/A
- PULM N/A
- Revenue Next Year
- ANEB N/A
- PULM $134.88
- P/E Ratio
- ANEB N/A
- PULM N/A
- Revenue Growth
- ANEB N/A
- PULM 6.96
- 52 Week Low
- ANEB $0.80
- PULM $1.72
- 52 Week High
- ANEB $3.30
- PULM $10.40
- Technical
- Relative Strength Index (RSI)
- ANEB 35.89
- PULM 35.76
- Support Level
- ANEB $0.94
- PULM $5.21
- Resistance Level
- ANEB $1.12
- PULM $6.07
- Average True Range (ATR)
- ANEB 0.14
- PULM 0.47
- MACD
- ANEB -0.03
- PULM -0.07
- Stochastic Oscillator
- ANEB 11.17
- PULM 17.33
About ANEB Anebulo Pharmaceuticals Inc.
Anebulo Pharmaceuticals Inc is a clinical-stage biotechnology company, developing novel solutions for people suffering from cannabinoid overdose and substance addiction. The product candidate, ANEB-001, is intended to reverse the negative effects of cannabinoid overdose within 1 hour of administration. The signs and symptoms of cannabinoid overdose range from profound sedation to anxiety and panic to psychosis with hallucinations.
About PULM Pulmatrix Inc.
Pulmatrix Inc is a clinical-stage biotechnology company. The company is focused on the discovery and development of novel inhaled therapeutic products intended to prevent and treat respiratory diseases and infections with significant unmet medical needs. Pulmatrix designs and develops inhaled therapeutic products based on its proprietary dry powder delivery technology, iSPERSE (inhaled Small Particles Easily Respirable and Emitted), which enables delivery of small or large molecule drugs to the lungs by inhalation for local or systemic applications. The iSPERSE powders are engineered to be small, dense particles with dispersibility and delivery to airways.